This slide show features pathology slides and PET/CT scans of prostate cancer, as well as various images of bone lesions from metastatic disease.
ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC
Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.
A Sneak Peek at 2025 ASCO From the GU Perspective
Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.
FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC
The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.
Finding Ways to Break the Mold in GU Oncology
Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.
CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer
The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.
Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC
Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.